Department of Orthopaedics, Peking University International Hospital, Life Park Road No 1 Life Science Park of Zhong Guancun, Changping District, Beijing, 102206, China.
BMC Musculoskelet Disord. 2022 May 2;23(1):410. doi: 10.1186/s12891-022-05361-2.
This study was a randomized controlled trial to evaluate efficacy and safety of the usage of intravenous tranexamic acid during posterior operation of multilevel thoracic spine stenosis for controlling perioperative blood loss.
Sixty eight patients with multilevel thoracic spine stenosis were randomized into the tranexamic acid group receiving 15 mg/kg body weight before the skin incision was made and 1 mg/kg body weight per hour during operation or the control group receiving the same dose of placebo (0.9% sodium chloride solution) intravenously. Pedicle screw fixation, laminectomy and selective discectomy were performed. Intraoperative and perioperative total blood loss were compared. The necessity and amount for blood transfusion, blood coagulation function, durations of postoperative hospital stays were compared. The complications of tranexamic acid were also investigated such as cardiovascular and cerebrovascular events, lower limb venous thrombosis.
There were no statistically significant differences in age, gender, body mass index, ASA status, pathology required surgery, preoperative hemoglobin, operation time, laminectomy segments and discectomy segments between the tranexamic acid and control groups. The intraoperative blood loss (455.9 ± 206.6 ml vs 580.6 ± 224.3 ml, p < 0.05) and total blood loss (675.3 ± 170.3 ml vs 936.8 ± 306.4 ml, p < 0.01) in tranexamic acid group were significant lower than those in control group. The means of blood unit transfused (2.5 ± 1.0 vs 4.7 ± 2.4, p < 0.05) and Hb reduction in 48 h (22.5 ± 3.4 g/L vs 25.3 ± 3.9 g/L, p < 0.01) were significantly lower in tranexamic acid group than that in control group. There were no statistically significant differences in blood coagulation function pre-operation or 48 h post-operation between the tranexamic acid and the control groups. The requirements for patients to receive blood transfusion were fewer and durations of post-operational hospital stays were shorter in the tranexamic acid group, however, the difference did not achieve statistical significance. There was no significant difference in superficial or deep venous thrombosis of lower limbs or deterioration of neurological function between tranexamic acid group and control group.
Application of intravenous tranexamic acid significantly reduces intraoperative and perioperative total blood loss without significant side effects in posterior operation of multilevel thoracic spine stenosis.
At Chinese Clinal Trial Registry. http://www.chictr.org.cn/ , ChiCTR2100054221. Registered on 11/12/2021.
本研究为一项随机对照试验,旨在评估静脉使用氨甲环酸在多节段胸椎狭窄后路手术中控制围手术期失血的疗效和安全性。
68 例多节段胸椎狭窄患者随机分为氨甲环酸组(切皮前给予 15mg/kg 体重,术中每小时给予 1mg/kg 体重)和对照组(给予相同剂量的安慰剂[0.9%氯化钠溶液]静脉注射)。行椎弓根螺钉固定、椎板切除术和选择性椎间盘切除术。比较术中及围手术期总失血量。比较输血的必要性和量、凝血功能、术后住院时间。还研究了氨甲环酸的并发症,如心血管和脑血管事件、下肢静脉血栓形成。
氨甲环酸组和对照组在年龄、性别、体重指数、ASA 状态、手术要求、术前血红蛋白、手术时间、椎板切除节段和椎间盘切除节段方面无统计学差异。氨甲环酸组术中失血量(455.9±206.6ml 比 580.6±224.3ml,p<0.05)和总失血量(675.3±170.3ml 比 936.8±306.4ml,p<0.01)明显低于对照组。氨甲环酸组输血的平均单位数(2.5±1.0 比 4.7±2.4,p<0.05)和 48 小时 Hb 减少量(22.5±3.4g/L 比 25.3±3.9g/L,p<0.01)明显低于对照组。两组术前及术后 48 小时凝血功能无统计学差异。氨甲环酸组输血需求减少,术后住院时间缩短,但差异无统计学意义。氨甲环酸组与对照组下肢浅静脉或深静脉血栓形成或神经功能恶化无显著差异。
在多节段胸椎狭窄后路手术中应用静脉注射氨甲环酸可显著减少术中及围手术期总失血量,且无明显副作用。
在中国临床试验注册中心。http://www.chictr.org.cn/,ChiCTR2100054221。注册于 2021 年 11 月 12 日。